Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1

著者: Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri, Gèrard Socié, Depei Wu, Liisa Volin, Didier Blaise, Nöel Milpied, Charles Craddock, Ibrahim Yakoub‐Agha, Johan Maertens, Per Ljungman, Anne Huynh, Mauricette Michallet, Éric Deconinck, Patrice Chevallier, Jakob Passweg, Fabio Ciceri, Mohamad Mohty, Jan J. Cornelissen, Arnon Nagler - Blood Advances 2017 被引用: 89

< .001). Nonrelapse mortality (NRM) depended on donor type and was estimated at 26 ± 3% and 29 ± 3% after haplo alloHSCT and UCB grafts at 2 years vs 15 ± 1% following MRD alloHSCT. Multivariable analysis confirmed the impact of donor type with OS following MRD, 10/10 MUD, and haplo alloHSCT not being statistically significantly different. NRM was significantly higher for alternative donors as compared with MRD alloHSCT. Collectively, these results suggest that alloHSCT with MRDs and 10/10 MUDs may still be preferred in patients with poor-risk AML in CR1. If an MRD or 10/10 MUD is not available, then the repertoire of alternative donors includes 9/10 MUD, UCB grafts, and haplo-identical donors. The latter type of donor is increasingly applied and now approximates results with matched donors.